Back to products

Brukinsa 80 mg Capsule

Brand Name: Brukinsa

Molecule: Zanubrutinib

Strength: 80 mg

Quantity: 120 Capsules

Form: Capsule

Packaging Type: Bottle

Manufacturer/Marketed By: Beigene

Country of Origin: China

No similar products found.

Overview

- Introduction
- Benefits
- Indications and Usage
- How it Works
- Dosage & Administration
- Side Effects
- Warning and Precaution
- Patient Guidance
- Clinical Trial & Approvals
- References
- FAQ

Description

Brukinsa 80 mg Capsule contains zanubrutinib, a targeted anticancer medicine classified as a Bruton’s tyrosine kinase (BTK) inhibitor. It is used in the treatment of certain B-cell malignancies, a group of blood cancers that affect white blood cells. By targeting specific signaling pathways that help cancer cells grow and survive, Brukinsa helps slow or reduce the progression of these conditions when used as prescribed by a qualified healthcare professional. Brukinsa is commonly used in adults diagnosed with conditions such as mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL), depending on regulatory approvals and physician guidance. It is taken orally in capsule form and is generally prescribed as part of a long-term treatment plan under medical supervision. Because targeted therapies can influence

Benefits

Targets BTK signaling, a key pathway involved in certain B-cell cancers
Oral capsule formulation that may allow outpatient treatment
Designed to provide selective BTK inhibition, which may help reduce disease progression in certain patients
May be used in patients who have received prior therapies depending on clinical guidance
Part of modern targeted therapy approaches used in hematologic oncology

Indications and Usage

Brukinsa (zanubrutinib) may be prescribed for adults for conditions such as:

Mantle Cell Lymphoma (MCL) in patients who have received prior therapy
Waldenström’s Macroglobulinemia (WM)
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Other approved B-cell malignancies, depending on regional regulatory approvals

Use is determined by an oncologist based on diagnosis, treatment history, and clinical guidelines.

How it Works

Zanubrutinib works by selectively inhibiting Bruton’s tyrosine kinase (BTK), an enzyme that plays a crucial role in the signaling pathway of B-lymphocytes, a type of white blood cell involved in immune function. In certain blood cancers, abnormal B-cells rely on BTK signaling to survive and multiply.

By blocking BTK activity, zanubrutinib interferes with these signals, which can reduce the growth and survival of malignant B-cells. This targeted approach focuses on molecular pathways associated with the disease, helping slow disease progression in some patients when used as prescribed and monitored by a healthcare professional.

Dosage & Administration

Brukinsa capsules are taken orally, usually once or twice daily depending on the prescribed regimen.
Capsules should be swallowed whole with water.
It may be taken with or without food, unless directed otherwise by a healthcare professional.
Do not crush, chew, or open capsules.
If a dose is missed, follow the guidance provided by the prescribing physician.
Treatment schedules and duration are determined by the oncologist based on clinical response and tolerance.

Side Effects

Common side effects

Decreased white blood cell counts
Upper respiratory infections
Bruising or bleeding
Rash
Diarrhea
Fatigue
Muscle or joint pain

Serious side effects

Severe infections
Major bleeding events
Low blood cell counts (neutropenia, thrombocytopenia, anemia)
Heart rhythm problems such as atrial fibrillation
Secondary malignancies including skin cancers

Patients should report unusual symptoms to their healthcare provider promptly.

Warning and Precaution

Risk of serious infections during treatment
Increased risk of bleeding or hemorrhage
Possible low blood cell counts, requiring routine monitoring
Potential heart rhythm disturbances, including atrial fibrillation
Risk of secondary cancers, particularly skin cancers
Inform the doctor before surgery or dental procedures
Pregnancy and breastfeeding considerations should be discussed with a healthcare provider
Use caution in patients taking blood thinners or antiplatelet medicines

Patient Guidance

Take the medicine exactly as prescribed by your oncologist
Attend regular blood tests and follow-up appointments
Report signs of infection, unusual bleeding, or heart symptoms
Avoid self-adjusting doses without medical advice
Inform healthcare providers about all medicines, supplements, and herbal products you use
Use sun protection due to potential skin cancer risk
Store the medicine according to recommended conditions

Clinical Trial & Approvals

Zanubrutinib has been evaluated in multiple clinical trials studying its effectiveness in B-cell malignancies, including mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia. Regulatory approvals have been granted in several regions, including by agencies such as the U.S. FDA and other international regulators, for specific indications based on clinical study outcomes and safety evaluations.

References

U.S. Food and Drug Administration (FDA).
Brukinsa (zanubrutinib) Prescribing Information.
https://www.accessdata.fda.gov
European Medicines Agency (EMA).
Brukinsa (zanubrutinib) – European Public Assessment Report.
https://www.ema.europa.eu
National Cancer Institute (NCI).
Zanubrutinib – Drug Information Summary.
https://www.cancer.gov
Drugs.com.
Zanubrutinib: Uses, Dosage, Side Effects, Warnings.
https://www.drugs.com
MedlinePlus – U.S. National Library of Medicine.
Zanubrutinib Drug Information.
https://medlineplus.gov
ClinicalTrials.gov.
Studies evaluating Zanubrutinib in B-cell malignancies.
https://clinicaltrials.gov
BeiGene Ltd.
Brukinsa (zanubrutinib) Official Product Information.
https://www.brukinsa.com
National Comprehensive Cancer Network (NCCN).
NCCN Guidelines for B-Cell Lymphomas and Chronic Lymphocytic Leukemia.

FAQ

What is Brukinsa 80 mg Capsule used for?+

It is used in the treatment of certain B-cell blood cancers, such as mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia, as prescribed by a doctor.

What is the active ingredient in Brukinsa?+

The active ingredient is zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor.

Is Brukinsa a chemotherapy drug?+

Brukinsa is considered a targeted therapy rather than traditional chemotherapy.

Do I need a prescription to obtain Brukinsa?+

Yes. Brukinsa is a prescription-only oncology medicine and should be used under specialist supervision.

How long is Brukinsa treatment usually continued?+

Treatment duration depends on the patient’s response, disease status, and medical guidance.

Can Brukinsa cause infections?+

Yes. Because it can affect immune cells, there may be an increased risk of infections.

Can Brukinsa interact with other medicines?+

Yes. Certain medicines, especially CYP3A inhibitors/inducers or blood thinners, may interact. Always inform your healthcare provider about other medications.

How should Brukinsa capsules be stored?+

Store at room temperature, protected from moisture and excessive heat, unless otherwise directed on the label.